OpenLobby.EU
Explore

Die Arzneimittel-Importeure e.V.

EU-GESUNDHEITSMARKT Wir fördern die Entwicklung des Parallel- und Reimports als Mittel zur Errichtung eines einheitlichen Marktes in der EU, der alle Bürgerinnen und Bürger mit Medikamenten zu annehmbaren Preisen versorgt. FREIER WETTBEWERB UND FREIER WARENVERKEHR Wir stellen die ursprünglich in den Römischen Verträgen festgelegten Prinzipien des uneingeschränkten Wettbewerbs (gemäß der Artikel 81 und 82 EGV, heute Art: 101, 102 AEUV) und des freien Warenverkehrs (gemäß der Artikel 34 und 36 AEUV) sicher. Wir wirken den Versuchen betroffener Parteien entgegen, die freie Wahl des Verbrauchers – unter Verletzung der Artikel 101 und 102 AEUV – einzuschränken. ARZNEIMITTELZULASSUNG Wir analysieren die Verfahren und Auswirkungen von Arzneimittelzulassungen durch die Aufsichtsbehörden sowie Herstellung, Vertrieb und Lieferung von Arzneimitteln im Parallel- und Reimport. AUFGABEN Unsere Aufgaben - gemäß den Verbandssatzungen - sind insbesondere: • Förderung eines Gedanke (...)

Lobbying Activity

Response to Evaluation of the Regulation on the functioning of the internal market

24 Mar 2017

The Association of German Parallel Distributors of Pharmaceuticals (VAD e.V.) wishes to submit its feedback to the Commission’s roadmap on the Evaluation of the functioning of Regulation (EC) 2679/98 on the functioning of the internal market in relation to the free movement of goods among Member states. The Internal Market and the free movement of goods are one of the cornerstones of the European Union. For this reason, defending the Internal Market against inappropriate measures that lead to a limited free movement of goods is one of the key challenges for the European Commission. The parallel distribution of pharmaceuticals is a guardian of the Internal Market, since it ensures the free movement of goods and supports healthy competition to the pharmaceutical markets. In this context, the distribution of pharmaceuticals fundamentally relies on the free movement of goods as it is described in the Regulation No 2679/98. The Regulation sets out clear measures to notify and address obstacles to the free movement of goods. According to the Regulation “Member States should abstain from adopting measures or engaging in conduct liable to constitute an obstacle to trade and, on the other hand, take all necessary and proportionate measures with a view to facilitating the free movement of goods in their territory”. Over the recent years, on the one hand some Member States have attempted to reduce the free movement of pharmaceuticals by establishing intra-EU export bans and on the other hand they have stopped notifying the Commission about these measures. The European Commission rightly dedicated its workforce in order to ask the member states to notify and to examine whether these export restrictions have been lawful or not and consequently objected some decisions taken by Member States. This example delivers a vital proof that it requires clear and strict rules at European level to safeguard the free movement of goods. It also shows that the Council Regulation is still relevant and delivers EU-added value. In our view, it is further important that the European Commission is equipped with clear competences to engage against violations of the Internal Market in a swift way and without excessive timelines. This should be reflected in all European regulation covering the Internal Market, including Regulation No 2679/98 EC.
Read full response